Cargando…
Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients
Malignant cells differ from benign ones in their metabolome and it is largely unknown whether this difference is reflected in the metabolic profile of their microvesicles (MV), which are secreted into the blood of cancer patients. Here, they are present together with MV from the various blood and en...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707654/ https://www.ncbi.nlm.nih.gov/pubmed/34948336 http://dx.doi.org/10.3390/ijms222413540 |
_version_ | 1784622488889589760 |
---|---|
author | Buentzel, Judith Klemp, Henry Gerd Kraetzner, Ralph Schulz, Matthias Dihazi, Gry Helene Streit, Frank Bleckmann, Annalen Menck, Kerstin Wlochowitz, Darius Binder, Claudia |
author_facet | Buentzel, Judith Klemp, Henry Gerd Kraetzner, Ralph Schulz, Matthias Dihazi, Gry Helene Streit, Frank Bleckmann, Annalen Menck, Kerstin Wlochowitz, Darius Binder, Claudia |
author_sort | Buentzel, Judith |
collection | PubMed |
description | Malignant cells differ from benign ones in their metabolome and it is largely unknown whether this difference is reflected in the metabolic profile of their microvesicles (MV), which are secreted into the blood of cancer patients. Here, they are present together with MV from the various blood and endothelial cells. Harvesting MV from 78 breast cancer patients (BC) and 30 controls, we characterized the whole blood MV metabolome using targeted and untargeted mass spectrometry. Especially (lyso)-phosphatidylcholines and sphingomyelins were detected in a relevant abundance. Eight metabolites showed a significant discriminatory power between BC and controls. High concentrations of lysoPCaC26:0 and PCaaC38:5 were associated with shorter overall survival. Comparing BC subtype-specific metabolome profiles, 24 metabolites were differentially expressed between luminal A and luminal B. Pathway analysis revealed alterations in the glycerophospholipid metabolism for the whole cancer cohort and in the ether lipid metabolism for the molecular subtype luminal B. Although this mixture of blood-derived MV contains only a minor number of tumor MV, a combination of metabolites was identified that distinguished between BC and controls as well as between molecular subtypes, and was predictive for overall survival. This suggests that these metabolites represent promising biomarkers and, moreover, that they may be functionally relevant for tumor progression. |
format | Online Article Text |
id | pubmed-8707654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-87076542021-12-25 Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients Buentzel, Judith Klemp, Henry Gerd Kraetzner, Ralph Schulz, Matthias Dihazi, Gry Helene Streit, Frank Bleckmann, Annalen Menck, Kerstin Wlochowitz, Darius Binder, Claudia Int J Mol Sci Article Malignant cells differ from benign ones in their metabolome and it is largely unknown whether this difference is reflected in the metabolic profile of their microvesicles (MV), which are secreted into the blood of cancer patients. Here, they are present together with MV from the various blood and endothelial cells. Harvesting MV from 78 breast cancer patients (BC) and 30 controls, we characterized the whole blood MV metabolome using targeted and untargeted mass spectrometry. Especially (lyso)-phosphatidylcholines and sphingomyelins were detected in a relevant abundance. Eight metabolites showed a significant discriminatory power between BC and controls. High concentrations of lysoPCaC26:0 and PCaaC38:5 were associated with shorter overall survival. Comparing BC subtype-specific metabolome profiles, 24 metabolites were differentially expressed between luminal A and luminal B. Pathway analysis revealed alterations in the glycerophospholipid metabolism for the whole cancer cohort and in the ether lipid metabolism for the molecular subtype luminal B. Although this mixture of blood-derived MV contains only a minor number of tumor MV, a combination of metabolites was identified that distinguished between BC and controls as well as between molecular subtypes, and was predictive for overall survival. This suggests that these metabolites represent promising biomarkers and, moreover, that they may be functionally relevant for tumor progression. MDPI 2021-12-17 /pmc/articles/PMC8707654/ /pubmed/34948336 http://dx.doi.org/10.3390/ijms222413540 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Buentzel, Judith Klemp, Henry Gerd Kraetzner, Ralph Schulz, Matthias Dihazi, Gry Helene Streit, Frank Bleckmann, Annalen Menck, Kerstin Wlochowitz, Darius Binder, Claudia Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients |
title | Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients |
title_full | Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients |
title_fullStr | Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients |
title_full_unstemmed | Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients |
title_short | Metabolomic Profiling of Blood-Derived Microvesicles in Breast Cancer Patients |
title_sort | metabolomic profiling of blood-derived microvesicles in breast cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8707654/ https://www.ncbi.nlm.nih.gov/pubmed/34948336 http://dx.doi.org/10.3390/ijms222413540 |
work_keys_str_mv | AT buentzeljudith metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT klemphenrygerd metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT kraetznerralph metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT schulzmatthias metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT dihazigryhelene metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT streitfrank metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT bleckmannannalen metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT menckkerstin metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT wlochowitzdarius metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients AT binderclaudia metabolomicprofilingofbloodderivedmicrovesiclesinbreastcancerpatients |